GlassScriptPhysician profile
Nasser Lavaud
NPI 1205207883
$2,597.83
in general payments reported to CMS, 2019-2025
10 companies · $405 in 2025
The $405 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $193 · 2022: $656 · 2023: $767 · 2024: $577 · 2025: $405.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,749.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,748.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $572.39 | 2021-2025 | Ingrezza |
| Acadia Pharmaceuticals INC | $524.50 | 2022-2025 | Nuplazid |
| Otsuka America Pharmaceutical, INC. | $392.00 | 2023-2024 | Nuedexta, Rexulti |
| Avanir Pharmaceuticals, INC. | $340.32 | 2021-2022 | |
| Alpha Cognition USA, INC. | $298.64 | 2025 | Zunveyl |
| Teva Pharmaceuticals USA, INC. | $296.26 | 2022-2024 | Austedo Xr, Austedo |
| Sun Pharmaceutical Industries INC. | $98.81 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $44.17 | 2022 | |
| Janssen Pharmaceuticals, INC | $17.15 | 2022 | |
| Urovant Sciences INC | $13.59 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nasser Lavaud listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.